Report of Foreign Issuer (6-k)
November 15 2018 - 4:42PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
November 2018
Commission file number: 001-36288
Akari
Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
x
Form
40-F
¨
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On November 15, 2018, Akari Therapeutics,
Plc, (the “Company”) issued a press release entitled “Akari Announces Coversin Data to be Presented at 2018 Complement-Based
Drug Development Summit.”
A copy of the press
release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The first three paragraphs and “Forward
Looking Statements” of the press release attached to this Form 6-K are hereby incorporated by reference into all effective
registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
|
|
|
|
99.1
|
Press Release dated November 15, 2018.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Akari Therapeutics, Plc
|
|
|
(Registrant)
|
|
|
|
|
|
|
By:
|
/s/ Clive Richardson
|
|
|
Name:
|
Clive Richardson
|
|
|
|
Interim Chief Executive Officer and Chief Operating Officer
|
|
Date: November 15, 2018
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024